MedKoo Cat#: 414893 | Name: PGL-135
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PGL-135 is a Polyglutamine Aggregation Inhibitor

Chemical Structure

PGL-135
PGL-135
CAS#26278-83-1

Theoretical Analysis

MedKoo Cat#: 414893

Name: PGL-135

CAS#: 26278-83-1

Chemical Formula: C9H10N2OS

Exact Mass: 194.0514

Molecular Weight: 194.25

Elemental Analysis: C, 55.65; H, 5.19; N, 14.42; O, 8.24; S, 16.50

Price and Availability

Size Price Availability Quantity
5mg USD 280.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PGL-135; PGL135; PGL 135
IUPAC/Chemical Name
2-Amino-4,7-dimethyl-6-benzothiazolol
InChi Key
RUTNKAMSWIPHJW-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H10N2OS/c1-4-3-6(12)5(2)8-7(4)11-9(10)13-8/h3,12H,1-2H3,(H2,10,11)
SMILES Code
OC1=CC(C)=C2N=C(N)SC2=C1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 194.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, Holt K, Sunshine S, Moffitt H, Sathasivam K, Woodman B, Wanker EE, Lowden PA, Bates GP. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis. 2006 Jan;21(1):228-36. doi: 10.1016/j.nbd.2005.07.007. Epub 2005 Aug 18. PMID: 16111888. 2: Lazarev VF, Benken KA, Semenyuk PI, Sarantseva SV, Bolshakova OI, Mikhaylova ER, Muronetz VI, Guzhova IV, Margulis BA. GAPDH binders as potential drugs for the therapy of polyglutamine diseases: design of a new screening assay. FEBS Lett. 2015 Feb 27;589(5):581-7. doi: 10.1016/j.febslet.2015.01.018. Epub 2015 Jan 24. PMID: 25625921. 3: Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem. 2011 Dec 30;286(52):44512-20. doi: 10.1074/jbc.M111.307587. Epub 2011 Oct 7. PMID: 21984825; PMCID: PMC3247975.